Literature DB >> 15081912

Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples.

Peter de Bruijn1, Edwin W Willems, Walter J Loos, Jaap Verweij, Alex Sparreboom.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15081912     DOI： 10.1016/j.ab.2004.01.007

Source DB:  PubMed          Journal:  Anal Biochem        ISSN： 0003-2697            Impact factor:   3.365


× No keyword cloud information.
  5 in total

1.  Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.

Authors:  D J Crona; J Ramirez; W Qiao; A-J de Graan; M J Ratain; R H N van Schaik; R H J Mathijssen; G L Rosner; F Innocenti
Journal:  Pharmacogenomics J       Date:  2015-04-14       Impact factor: 3.550

2.  Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice.

Authors:  Sander A Huisman; Peter de Bruijn; Inge M Ghobadi Moghaddam-Helmantel; Jan N M IJzermans; Erik A C Wiemer; Ron H J Mathijssen; Ron W F de Bruin
Journal:  Br J Pharmacol       Date:  2016-02-08       Impact factor: 8.739

3.  Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.

Authors:  Antonio Jimeno; Michelle A Rudek; Thomas Purcell; Daniel A Laheru; Wells A Messersmith; Janet Dancey; Michael A Carducci; Sharyn D Baker; Manuel Hidalgo; Ross C Donehower
Journal:  Cancer Chemother Pharmacol       Date:  2007-04-12       Impact factor: 3.333

4.  Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.

Authors:  Sanjay Goel; Kavita Desai; Sirisha Karri; Radharani Gollamudi; Imran Chaudhary; Anca Bulgaru; Andreas Kaubisch; Gary Goldberg; Mark Einstein; Fernando Camacho; Sharyn Baker; Sridhar Mani
Journal:  Invest New Drugs       Date:  2006-12-30       Impact factor: 3.651

5.  Effects of methimazole on the elimination of irinotecan.

Authors:  Jessica M van der Bol; Theo J Visser; Walter J Loos; Floris A de Jong; Erik A C Wiemer; Maarten O van Aken; Andre S Planting; Jan H Schellens; Jaap Verweij; Ron H J Mathijssen
Journal:  Cancer Chemother Pharmacol       Date:  2010-08-01       Impact factor: 3.333
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.